It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
More and more in-depth studies have revealed that the occurrence and development of tumors depend on gene mutation and tumor heterogeneity. The most important manifestation of tumor heterogeneity is the dynamic change of tumor microenvironment (TME) heterogeneity. This depends not only on the tumor cells themselves in the microenvironment where the infiltrating immune cells and matrix together forming an antitumor and/or pro-tumor network. TME has resulted in novel therapeutic interventions as a place beyond tumor beds. The malignant cancer cells, tumor infiltrate immune cells, angiogenic vascular cells, lymphatic endothelial cells, cancer-associated fibroblastic cells, and the released factors including intracellular metabolites, hormonal signals and inflammatory mediators all contribute actively to cancer progression. Protein post-translational modification (PTM) is often regarded as a degradative mechanism in protein destruction or turnover to maintain physiological homeostasis. Advances in quantitative transcriptomics, proteomics, and nuclease-based gene editing are now paving the global ways for exploring PTMs. In this review, we focus on recent developments in the PTM area and speculate on their importance as a critical functional readout for the regulation of TME. A wealth of information has been emerging to prove useful in the search for conventional therapies and the development of global therapeutic strategies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University of Electronic Science and Technology of China, Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, Chengdu, P. R. China (GRID:grid.54549.39) (ISNI:0000 0004 0369 4060)
2 University of Electronic Science and Technology of China, Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, Chengdu, P. R. China (GRID:grid.54549.39) (ISNI:0000 0004 0369 4060); Guangxi Medical University, Guangxi Collaborative Innovation Center for Biomedicine (Guangxi-ASEAN Collaborative Innovation Center for Major Disease Prevention and Treatment), Nanning, China (GRID:grid.256607.0) (ISNI:0000 0004 1798 2653)
3 Third Military Medical University (Army Medical University), Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Chongqing, China (GRID:grid.410570.7) (ISNI:0000 0004 1760 6682)
4 Wake Forest University, Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318)
5 University of Electronic Science and Technology of China, Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, Chengdu, P. R. China (GRID:grid.54549.39) (ISNI:0000 0004 0369 4060); Wake Forest University, Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318)